Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)		3 Months Ended			6 Months Ended
		Feb. 28, 2023		Feb. 28, 2022	Feb. 28, 2023	Feb. 28, 2022
Income Statement [Abstract]
REVENUE		$ 93,921		$ 7,631	$ 348,461	$ 22,436
OPERATING EXPENSES
Research and development expenses		(110,410)		(114,896)	(216,688)	(261,179)
Sales and marketing expenses		(3,163)		(33,764)	(16,946)	(247,536)
General and administrative expenses		(769,108)		(1,110,932)	(1,467,727)	(2,781,422)
LOSS FROM OPERATIONS		(788,760)		(1,251,961)	(1,352,900)	(3,267,701)
Interest expense		(30,937)		(22,196)	(61,601)	(50,696)
Loss on change in fair value of convertible notes				(1,076,830)		(1,181,330)
OTHER (EXPENSE) INCOME
Exchange difference, net		75,294		(30,974)	(49,915)	(6,054)
Other income – from non-related parties		17,473		80	18,413	531
Total other (expense) income		92,767		(30,894)	(31,502)	(5,523)
LOSS BEFORE INCOME TAX		(726,930)		(2,381,881)	(1,446,003)	(4,505,250)
Income tax benefit				4,482		8,964
NET LOSS		(726,930)		(2,377,399)	(1,446,003)	(4,496,286)
OTHER COMPREHENSIVE LOSS
Foreign currency translation adjustment		(79,592)		35,460	52,781	11,083
TOTAL COMPREHENSIVE LOSS		$ (806,522)		$ (2,341,939)	$ (1,393,222)	$ (4,485,203)
Net loss per share - Basic and diluted		$ (0.00)	[1],[2]	$ (0.02)	$ (0.01)	$ (0.03)
Weighted average number of shares of common stock outstanding – Basic and diluted	[3]	202,304,158		170,033,710	201,084,637	165,431,246

[1] Less than $0.01

[2] Less than $0.01 per share

[3] Including 4,522,262 shares granted and vested but not yet issued for the period ended February 28, 2023; and including 1,600,000 shares converted from convertible notes but not yet issued and 4,578,868 shares that were granted and vested but not yet issued for the period ended February 28, 2022.